Abstract
Atherosclerosis is a chronic process related to several underlying mechanisms leading to the formation and evolution of atherosclerotic plaque. Of great interest are during the last years short, non-coding RNAs, called microRNAs and responsible for several aspects of homeostasis and disease. According to the available data microRNAs are expressed in the cardiovascular system and have key roles in normal states, as well as in disease development and progression. Moreover, it has been shown that they contribute to atherogenesis, coronary artery disease and myocardial infarction. Importantly, microRNAs circulate in the bloodstream, while they exist in tissues, affect plaque initiation and progression and seem to be essential biomarkers of atherosclerosis. Therefore, understanding the role of these molecules may be of great importance in the understanding of the pathogenesis of atheromatous plaque providing new evidence for diagnosis and treatment of atherosclerosis and its' clinical presentation.
Keywords: miRNAs, atherosclerosis, plaque progression, non-coding RNAs, homeostasis, coronary artery disease, myocardial infarction, biomarkers, cardiovascular system, plaque initiation
Current Pharmaceutical Design
Title:The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque
Volume: 19 Issue: 9
Author(s): Nikolaos Papageorgiou, Dimitris Tousoulis, Emmanuel Androulakis, Anna Kontogeorgou, Marietta Charakida, Anastasios Giolis, Katerina Siama, Athanasios Trikas, Alexandros Briasoulis, Christos Pitsavos and Christodoulos Stefanadis
Affiliation:
Keywords: miRNAs, atherosclerosis, plaque progression, non-coding RNAs, homeostasis, coronary artery disease, myocardial infarction, biomarkers, cardiovascular system, plaque initiation
Abstract: Atherosclerosis is a chronic process related to several underlying mechanisms leading to the formation and evolution of atherosclerotic plaque. Of great interest are during the last years short, non-coding RNAs, called microRNAs and responsible for several aspects of homeostasis and disease. According to the available data microRNAs are expressed in the cardiovascular system and have key roles in normal states, as well as in disease development and progression. Moreover, it has been shown that they contribute to atherogenesis, coronary artery disease and myocardial infarction. Importantly, microRNAs circulate in the bloodstream, while they exist in tissues, affect plaque initiation and progression and seem to be essential biomarkers of atherosclerosis. Therefore, understanding the role of these molecules may be of great importance in the understanding of the pathogenesis of atheromatous plaque providing new evidence for diagnosis and treatment of atherosclerosis and its' clinical presentation.
Export Options
About this article
Cite this article as:
Papageorgiou Nikolaos, Tousoulis Dimitris, Androulakis Emmanuel, Kontogeorgou Anna, Charakida Marietta, Giolis Anastasios, Siama Katerina, Trikas Athanasios, Briasoulis Alexandros, Pitsavos Christos and Stefanadis Christodoulos, The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090012
DOI https://dx.doi.org/10.2174/1381612811319090012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epinephrine and its Role in the Development of Obesity and Hypertension
Current Hypertension Reviews Editorial (Thematic Issue: Pharmacological Considerations in Anesthesiology- From Organ Failure to Transplantation)
Current Clinical Pharmacology TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?
Current Vascular Pharmacology Editorial (Hot Topic: Metabolic Syndrome and Cardiovascular Health: A Look Beyond the Horizon)
Current Pharmaceutical Design Ginsenosides from the Leaves and Flower Buds of Panax ginseng and their Pharmacological Effects
Current Bioactive Compounds Lung Ultrasound in the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis
Current Vascular Pharmacology Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment
Current Stem Cell Research & Therapy MicroRNAs and Ischemic Heart Disease: Towards a Better Comprehension of Pathogenesis, New Diagnostic Tools and New Therapeutic Targets
Recent Patents on Cardiovascular Drug Discovery Is Educational Attainment Associated with Increased Risk of Mortality in People with Dementia? A Population-based Study
Current Alzheimer Research Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs
Current Pharmaceutical Design Proline-Rich Peptides: Multifunctional Bioactive Molecules as New Potential Therapeutic Drugs
Current Protein & Peptide Science Risk Factors for Development of Heart Failure
Current Cardiology Reviews Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Inhibition of Sumoylation Alleviates Oxidative Stress-induced Retinal Pigment Epithelial Cell Senescence and Represses Proinflammatory Gene Expression
Current Molecular Medicine Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Therapy Of Cardiac Arrhythmias In Children: An Emerging Role Of Electroanatomical Mapping Systems
Current Vascular Pharmacology Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Newer Advances in Cardiovascular Metabolism and Diagnostic Technologies)
Current Pharmaceutical Design microRNAs: Innovative Targets for Cerebral Ischemia and Stroke
Current Drug Targets